Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant letrozole in ER-positive/HER2-negative breast cancer
KCT0008323Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of letrozole in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Nov 2017; status: active, not recruiting.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0008323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008323.